IVA vs MDGL vs AKBA vs HALO vs CLDX

For growth investors, Madrigal Pharmaceuticals, Inc.

(MDGL) is the stronger pick with 432. 1% revenue growth year-over-year, versus -78. 6% for Celldex Therapeutics, Inc. (CLDX). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 27. 1x trailing P/E (8. 6x forward), making it the more compelling value choice. Analysts rate Inventiva S. A. (IVA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Madrigal Pharmaceuticals, Inc.

(MDGL) delivered a total return of +346. 6%, compared to -75. 2% for Inventiva S. A. (IVA). Over 10 years, the gap is even starker: MDGL returned +39. 4% versus AKBA's -89. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Madrigal Pharmaceuticals, Inc.

(MDGL) is the lower-risk stock at 0. 49β versus Inventiva S. A. 's 1. 59β — meaning IVA is approximately 221% more volatile than MDGL relative to the S&P 500. On balance sheet safety, Celldex Therapeutics, Inc. (CLDX) carries a lower debt/equity ratio of 0% versus 44% for Halozyme Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Madrigal Pharmaceuticals, Inc.

(MDGL) is pulling ahead at 432. 1% versus -78. 6% for Celldex Therapeutics, Inc. (CLDX). On earnings-per-share growth, the picture is similar: Akebia Therapeutics, Inc. grew EPS 93. 7% year-over-year, compared to -59. 2% for Celldex Therapeutics, Inc.. Over a 3-year CAGR, IVA leads at 29. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus -172. 5% for Celldex Therapeutics, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -191. 6% for CLDX. At the gross margin level — before operating expenses — IVA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for AKBA: 332.

7% to $4. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 58), +701. 6% 10Y return). Inventiva S. A. (IVA) carries a higher beta of 1. 59 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HALO: +701. 6%, IVA: -71. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IVA is a small-cap quality compounder stock; MDGL is a mid-cap high-growth stock; AKBA is a small-cap high-growth stock; HALO is a small-cap high-growth stock; CLDX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.